Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3771-3777

  Brown, Ashley N ^a   Adams, Jonathan R ^a   Baluya, Dodge L ^a   Drusano, George L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALTEGRAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE INHIBITOR;

ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG HALF LIFE; FLOW CYTOMETRY; HOLLOW FIBER; HOLLOW FIBER INFECTION MODEL SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; BIOLOGICAL MODEL; CELL LINE; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; HEK293 CELL LINE; HIV INFECTIONS; PATIENT COMPLIANCE; RADIATION DOSE FRACTIONATION; T LYMPHOCYTE; VIROLOGY;

ANTI-HIV AGENTS; AREA UNDER CURVE; CELL LINE; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HEK293 CELLS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MODELS, BIOLOGICAL; PATIENT COMPLIANCE; RALTEGRAVIR POTASSIUM; T-LYMPHOCYTES;

EID: 84935915969     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00469-15     Document Type: Article

References (26)

1. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P. 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374:796-806. http://dx.doi.org/10.1016/S0140-6736(09)60918-1.
2. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 43:509-515. http://dx.doi.org/10.1097/QAI.0b013e31802b4956.
3. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46:125-133. http://dx.doi.org/10.1097/QAI.0b013e318157131c.
4. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H. 2009. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 52:350-356. http://dx.doi.org/10.1097/QAI.0b013e3181b064b0.
5. Rockstroh JK, Lennox JL, DeJesus E, Saag MS, Lazzarin A, Wan H, Walker ML, Xu X, Zhao J, Teppler H, DiNubile MJ, Rodgers AJ, Nguyen BY, Leavitt R, Sklar P. 2011. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 53:807-816. http://dx.doi.org/10.1093/cid/cir510.
6. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Zhong L, Cheng AK, McColl D, Kearney BP. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 43:1-5. http://dx.doi.org/10.1097/01.qai.0000233308.82860.2f.
7. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269. http://dx.doi.org/10.1016/S0140-6736(07)60597-2.
8. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY. 2010. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 50:605-612. http://dx.doi.org/10.1086/650002.
9. th Int Workshop Clin Pharmacol HIV Ther, Amsterdam, Netherlands, 15 to 17 April 2009.
10. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL, III, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 55:4552-4559. http://dx.doi.org/10.1128/AAC.00157-11.
11. th Int Workshop Clin Pharmacol HIV Ther, Amsterdam, Netherlands, 15 to 17 April 2009.
12. Eron JJ, Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY. 2011. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 11:907-915. http://dx.doi.org/10.1016/S1473-3099(11)70196-7.
13. Witmer M, Danovich R. 2009. Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses. Methods 47:277-282. http://dx.doi.org/10.1016/j.ymeth.2009.02.025.
14. Brown AN, McSharry JJ, Weng Q, Driebe EM, Engelthaler DM, Sheff K, Keim PS, Nguyen J, Drusano GL. 2010. In vitro system for modeling influenza A virus resistance under drug pressure. Antimicrob Agents Chemother 54:3442-3450. http://dx.doi.org/10.1128/AAC.01385-09.
15. McSharry JJ, Deziel MR, Zager K, Weng Q, Drusano GL. 2009. Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 53:129-135. http://dx.doi.org/10.1128/AAC.00708-08.
16. McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL. 2009. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 53:2375-2381. http://dx.doi.org/10.1128/AAC.00167-09.
17. Drusano GL, Bilello PA, Symonds WT, Stein DS, McDowell J, Bye A, Bilello JA. 2002. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob Agents Chemother 46:464-470. http://dx.doi.org/10.1128/AAC.46.2.464-470.2002.
18. Drusano GL, Bilello JA, Preston SL, O'Mara E, Kaul S, Schnittman S, Echols R. 2001. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis 183:1126-1129. http://dx.doi.org/10.1086/319281.
19. Iwamoto M, Wenning LA, Petry AS, Laethem M, De SM, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA. 2008. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 83:293-299. http://dx.doi.org/10.1038/sj.clpt.6100281.
20. Temesgen Z, Siraj DS. 2008. Raltegravir: first in class HIV integrase inhibitor. Ther Clin Risk Manag 4:493-500. http://dx.doi.org/10.2147/TCRM.S2268.
21. Metifiot M, Johnson B, Smith S, Zhao XZ, Marchand C, Burke T, Hughes S, Pommier Y. 2011. MK-0536 inhibits HIV-1 integrases resistant to raltegravir. Antimicrob Agents Chemother 55:5127-5133. http://dx.doi.org/10.1128/AAC.05288-11.
22. Croxtall JD, Lyseng-Williamson KA, Perry CM. 2008. Raltegravir. Drugs 68:131-138. http://dx.doi.org/10.2165/00003495-200868010-00009.
23. Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, Nguyen BY, Sklar P, Eron JJ, Jr, Wenning L. 2012. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother 56:3101-3106. http://dx.doi.org/10.1128/AAC.06417-11.
24. Cattaneo D, Gervasoni C, Meraviglia P, Landonio S, Fucile S, Cozzi V, Baldelli S, Pellegrini M, Galli M, Clementi E. 2012. Inter- and intrapatient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother 67:460-464. http://dx.doi.org/10.1093/jac/dkr498.
25. Brainard DM, Friedman EJ, Jin B, Breidinger SA, Tillan MD, Wenning LA, Stone JA, Chodakewitz JA, Wagner JA, Iwamoto M. 2011. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol 51:422-427. http://dx.doi.org/10.1177/0091270010367652.
26. Brown AN, Bulitta JB, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL. 2011. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob Agents Chemother 55:1747-1753. http://dx.doi.org/10.1128/AAC.01629-10.